 |
Year
2007 |
|
Archives
|
|
|
Indians love Viagra and how!
APRIL 06, 2005
AHMEDABAD: Viagra arrived in the Indian Erectile dysfunction market five years back. Since they arrived on the scene, drugs for erectile dysfunction (generic versions of the famed Viagra) have been able to penetrate the Indian market in a big way. In other ways, this sub-continent has witnessed a growth in the generic version of different brand names Viagra.
Data from research agency ORG-IMS reveal sale of these drugs grew almost 25 times from Rs 4 crore in 2000-01 (March to February) to Rs 102 crore in the same period of 2004-05. The erectile dysfunction market is flooded with generic versions like Kamagra, Silagra, Edegra, Soft Tabs and other lozenges.
However, the year-on-year growth rate for erectile dysfunction drugs which was at a high of 667 per cent in the first year (between 2000-01 and 2001-02) primarily because of the low base, has slowed down over the years. It dipped to 39.79 per cent between 2002-03 and 2003-04, and further to 35.43 per cent between 2003-04 to 2004-05, according to the ORG-IMS retail audit data.
At the same time, sale of all drugs for sexual
disorder (which includes drugs for other sexual problems) has
increased almost 3.5 times to nearly Rs 133.5 crore in the period
March 2004-February 2005 from Rs 38 crore in the same period in
2001. Drugs exclusively meant for erectile
dysfunction constitute 76 per cent of the sexual disorder segment.
"Cases of hypertension, diabetes and other neuropsychological problems and consequent lack in sexual desire are on the rise due to change in lifestyle, increasing competition and food habits," says Ganesh Nayak, executive director of Zydus Cadila, makers of Penegra, one of the ED brands in India.
The highest seller in the category, however, is Manforce manufactured by the Delhi-based Mankind Pharma, followed by Penegra, Caverta from Ranbaxy and Megalis from Macleods.
Interestingly, while the growth rate for sexual disorder drugs has actually increased in the past year, the growth rate for all other therapeutic segments namely anti-diabetic, cardiovascular, cholesterol reducers in the lifestyle related category industry has declined.
source:- http://economictimes.indiatimes.com
| 
